Assessing the effects of risankizumab on psoriasis in adults in Taiwan
Prospective Observational Cohort Study of Patients With Moderate to Severe Chronic Plaque Psoriasis in Taiwan
This study is testing how well a new psoriasis treatment called risankizumab works for adults in Taiwan compared to other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | AbbVie Industry-sponsored |
| Drugs / interventions | risankizumab |
| Locations | 8 sites (Taipei City, Taipei and 7 other locations) |
| Trial ID | NCT04818385 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of risankizumab, a biologic treatment for moderate to severe plaque psoriasis, by measuring the Psoriasis Area and Severity Index (PASI) 90 response in adult participants. Approximately 240 participants will be enrolled, with 160 receiving risankizumab and 80 receiving other biologics. The study will compare the durability of response between these treatments in a real-world setting across various locations in Taiwan. Participants must be initiating biologic treatment as determined by their healthcare provider.
Who should consider this trial
Good fit: Ideal candidates include adults with a confirmed diagnosis of moderate to severe chronic plaque psoriasis who are starting a biologic treatment.
Not a fit: Patients who are not initiating a biologic treatment or have participated in another clinical trial within the last 30 days may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the long-term effectiveness of risankizumab compared to other treatments for psoriasis, potentially improving patient care.
How similar studies have performed: Other studies have shown positive outcomes with biologic treatments for psoriasis, suggesting that this approach may yield valuable data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist t at the time of recruitment. * Initiating an approved biologic treatment for psoriasis as per regulatory and reimbursement policy in Taiwan. Physician's decision with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study. * Treatments prescribed in accordance to both the product monograph, regulatory and reimbursement policies in Taiwan. Exclusion Criteria: - Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in another PMOS or Registry is acceptable.
Where this trial is running
Taipei City, Taipei and 7 other locations
- National Taiwan University Hospital /ID# 230017 — Taipei City, Taipei, Taiwan (Recruiting)
- National Taiwan University Hospital - Hsinchu branch /ID# 238432 — Hsinchu City, Taiwan (Recruiting)
- Hualien Tzu Chi Hospital /ID# 238431 — Hualien City, Taiwan (Recruiting)
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 230016 — Kaohsiung, Taiwan (Recruiting)
- China Medical University Hospital /ID# 229961 — Taichung, Taiwan (Recruiting)
- National Cheng Kung University Hospital /ID# 253776 — Tainan, Taiwan (Recruiting)
- Taipei Medical University Hospital /ID# 230018 — Taipei City, Taiwan (Recruiting)
- Linkou Chang Gung Memorial Hospital /ID# 253775 — Taoyuan City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Abbvie Call Center
- Email: abbvieclinicaltrials@abbvie.com
- Phone: 844-663-3742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.